Skip to main content
. 2019 Oct 9;12:3169–3188. doi: 10.2147/IDR.S159952

Table 1.

Main Characteristics Of Available MenB Vaccines:27,131 4cmenb And rLP2086

4CMenB Vaccine rLP2086 Vaccine
Age From 6 to 8 weeks From 10 years
Posology

  • Infants: 3+1/2+1 (from 3 months)

  • From 2 to 10 years: 2 doses

  • From 10 years: 2 doses (Separated 1 month)

  • Infants: Not authorized for use

  • From 2 to 10 years: Not authorized

  • From 10 years: 2 doses (0–6 months) or 3 doses (0–1/2–6 months)
Cross-protection In vitro: The genes encoding for the antigens fHbp, NHBA, and NadA can be present and expressed in other serogroups, suggesting a potential impact of MenB vaccines against non-B strains
Clinical: Neisseria gonorrhea		 In vitro: The genes encoding for fHbp antigen can be present and expressed in other serogroups, suggesting a potential impact of MenB vaccines against non-B strains
Clinical: unknown
Number of components/antigens 4 different components/antigens

  1. Recombinant fusion protein comprised NHBA (peptide 2) and accessory protein 953 derived from N. meningitidis strains NZ98/254 and 2996, respectively

  2. Recombinant N. meningitidis group B NadA protein (fragment of the full-length protein derived from N. meningitidis strain 2996 (peptide 8 variant 2/3))

  3. Recombinant fusion protein comprised fHbp (variant 1.1) and the accessory protein 936 derived from N. meningitidis strains MC58 and 2996, respectively

  4. Outer membrane vesicle N. meningitidis group B NZ98/254 (B:4:P1.7–2,4) (expressing outer membrane protein PorA serosubtype P1.4)

 2 components, variants of 1 single antigen

  1. Recombinant fHBP subfamily A (A05)

  2. Recombinant fHBP subfamily B (B01)
Nasopharyngeal impact ± Preliminary data No data available
Duration of protection Immune persistence data
7,5 years79 		Immune persistence data
– 4−5 years109
Special groups Complement deficiencies, asplenia, splenic dysfunction, and those receiving eculizumab No data available
Effectiveness

  • UK data (2+1) – after 2 doses: 83% against all strains, 94% against vaccine strains – after Booster: 82% (−81–97%)

  • Canada data (Quebec) 2 months-20 years– 78% reduction

 No data available
Strain coverage prediction MATS assess if strain expressed antigens are recognized by the vaccine induced antibodies (basing on the variant and quantity of expressed antigen),

  • 70% – UK strains

  • 78% – EU strains

  • 91% – US strains

 MEASURE assess level of expressed antigen regardless of if the antigen is or not recognized by the vaccine induced antibodies (in 2.150 strains from EU, US, and Canada, 91% of the strains expressed sufficient levels of fHbp susceptible to bactericidal activity by vaccine antibodies)
Bactericidal activity Serum bactericidal antibodies were measured with hSBA assays using 3 strains selected to measure responses to fHbp, NadA, or PorA.
Proportion of subjects who achieved a 4-fold or greater increase in hSBA titer for each of the 3 strains was 88% against representative strains in the UK (higher estimation than with MATS)		 The vaccine was then tested for hSBA against the representative strains of different fHbp type, (PMB3302 (A04), PMB1256 (B03), PMB2001 (A56), PMB2707 (B44), PMB1321 (A22), and PMB2948 (B24).
Proportion of subjects who achieved hSBA titers >1:8–16 (depending on the strain) was 80% against different representative strains
Antigenic expression % invasive strains expressing each vaccine antigen at levels that predict bactericidal activity

  • 63.2% – fHbp variant 1

  • 59.3% – NHBA

  • 1.5% – NadA

  • 20.2% – PorA P1.4.

 >96% of the MenB strains in Europe express fHbp A o B (2 variants A 30% and B 70%)
Presence of the gene >99% of the invasive strains of Men B contains genes from at least 1 component of 4CMenB >99% of the invasive strains of Men B contains genes from at least 1 component of rLP2806